Trials / Recruiting
RecruitingNCT06478472
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Orelabrutinib combined with rituximab (OR) therapy were used to assess the efficacy and safety for newly diagnosed Marginal zone cell lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orelabrutinib in combination with rituximab | Induction Phase: Orelabrutinib + rituximab for a total of 6 cycles of 28 days each Obrutinib (O) 150mg oral d1-28 Rituximab (R) 375mg/m2 IV d0 Maintenance phase: Orelabrutinib 150mg po qd 24 cycles of 28 days each |
Timeline
- Start date
- 2024-06-23
- Primary completion
- 2027-06-23
- Completion
- 2027-06-23
- First posted
- 2024-06-27
- Last updated
- 2024-07-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06478472. Inclusion in this directory is not an endorsement.